CCND1 and non-small cell lung carcinoma: The CCND1 A870G polymorphism further modulates NSCLC risk, where the GG genotype intensifies smoking-associated carcinogenesis (≥40 pack-years) and improves response to platinum-based chemotherapy, suggesting its utility in treatment stratification [43].